News & Views
Merck and Sanofi-aventis laboratories to collaborate on cancer research
Dec 20 2010
In particular, the companies' laboratories will work on testing different combinations of agents that could potentially be used to block specific pathways in cancer cells.
The research will involve Merck Serono's MEK inhibitor MSC1936369B, the PI3K/mTOR inhibitor SAR245409 from Sanofi-aventis and the Class I PI3K inhibitor SAR245408.
Dr Wolfgang Wein, Merck Serono's executive vice-president for oncology, said the need to create more personalised cancer care makes it a "logical step" to explore how "new, exciting molecules" can be combined across development pipelines.
Sanofi-aventis senior vice-president and head of global oncology Dr Debasish Roychowdhury added: "This collaboration reinforces our commitment to maximise our portfolio and to provide better treatments for patients with cancer."
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK
May 21 2024 Lagos, Nigeria